Health Economics and Cost/Decision Analysis
|
|
- Douglas Tucker
- 5 years ago
- Views:
Transcription
1 Health Economics and Cost/Decision Analysis Samuel Finlayson, MD, MPH, FACS Department of Surgery University of Utah School of Medicine
2 Resources Constrained Every decision to provide a service represents an implicit decision not to provide some other service. (opportunity cost)
3 Provide cost-conscious care minimize cost maximize benefit PROVIDE VALUE
4 Glossary for Economic Analysis Cost-minimization Cost-benefit Cost-effectiveness Cost-utility
5 Cost Minimization Consider interventions A and B A and B both work. A costs less. Use A.
6 Cost-Benefit Interventions A and B A and B have costs: C A and C B A and B have outcomes: O A and O B (valued $) Compare A and B: C A /O A versus C B /O B
7 Cost-Effectiveness Interventions A and B again A and B have costs: C A and C B A and B have outcomes: O A and O B This time measured as health outcome (not $) e.g. lives saved, infections prevented, etc.
8 Cost-Effectiveness NET or INCREMENTAL cost-effectiveness C A -C B O A -O B
9 Utility and QALY Utility is measure of the value of a health state How much time in perfect health is your current health state worth? (time trade off) QALY = utility x year E.g. if one year in perfect health = 2 years with paraplegia then a year with paraplegia is 0.5 QALYs. (and utility of life with paraplegia = 0.5)
10 Cost-utility Type of cost effectiveness analysis based on utility (QALY) Expresses cost-effectiveness in terms of $ per QALY C A -C B QALY A -QALY B
11 How are economic analyses conducted? Clinical trials Decision models
12 Decision Analysis Quantitative, systematic approach to evaluating risks and benefits (tradeoffs) of an intervention Uses multiple data sources ( synthetic )
13 You re the Football Coach You are losing You have the ball 5 yards from the goal line 5 seconds left in the game Your call?
14 Summary of Steps 1. Model the decision 2. Apply probabilities of events 3. Apply value of outcomes 4. Analyze
15 1. Model the Decision
16 2. Assign Probabilities
17 3. Assign Values to Outcomes
18 4. Analyze (0.5*0.9) + (0*0.1) = 0.45 (1.0*0.4) + (0*0.6) = 0.40 Baseline analysis: FG strategy (0.45) preferred Typically also apply sensitivity analysis
19 Medical Decisions More complex Want to include costs/value
20 1. Model the decision survive Lose weight Bariatric surgery Don t lose wt. decide die Lose weight Diet & exercise Don t lose weight
21 2. Add probabilities 0.95 Bariatric surgery survive Lose weight Don t lose wt. decide 0.05 die Diet & exercise Lose weight Don t lose weight
22 3. Add values of outcomes LE U QALY 0.95 Bariatric surgery survive Lose weight Don t lose wt decide 0.05 die Diet & exercise 0.1 Lose weight Don t lose weight
23 4. Analysis EV = (0.1)(40)+(0.9)(24) = 25.6 QALY 0.95 Bariatric surgery survive Lose weight Don t lose wt. QALY decide 0.05 die 0 Diet & exercise 0.1 Lose weight Don t lose weight 24
24 4. Analysis QALY 36.5 decide 0.95 Bariatric surgery 0.05 survive die Lose weight Don t lose wt Diet & exercise 0.1 Lose weight Don t lose weight 24
25 How does one get from DA to CEA? Consider costs an outcome in the model
26 Add costs for CEA Lose weight Don t lose wt. Bariatric surgery 36.5 (Need to include decide 25.6 $$$ $ Diet & exercise survive die Lose weight Don t lose weight $ $ $ downstream costs as well)
27 Add costs for CEA $450, decide $$$ Bariatric surgery survive die Lose weight $ Don t lose wt $150,000 $ Diet & exercise Lose weight Don t lose weight $ $
28 Cost-Effectiveness NET or INCREMENTAL cost-effectiveness C A -C B O A -O B
29 Incremental Cost-Effectiveness Cost ($) Effect (QALY) Bariatric Surgery 450, Diet & Exercise 150, Net cost/effect 300, C/E ratio = $300,000/10.9 QALY = $27,500/QALY Interpretation: cost-effective
30 higher cost lower utility higher cost greater utility Utility alternative lower cost lower utility lower cost greater utility dominant Cost
31 How is CEA used? Common role for CEA informing decisions about individual interventions, identifying the best buy Common targets interventions that are new, controversial, or in direct competition with an accepted alternative treatment (CEA can be used to make an argument for additional expenditure)
32 Summary 1. DA synthesizes data from multiple sources and models clinical choices to estimate the relative benefits of competing interventions 2. Economic analysis measures the relative value interventions -- the cost of the additional health benefit -- to help establish priorities in resource allocation.
Introduction to Cost-Effectiveness Analysis
Introduction to Cost-Effectiveness Analysis Janie M. Lee, MD, MSc RSNA Clinical Trials Methodology Workshop January 13, 2016 Why is Clinical Research Important to Radiology? Radiology currently occupies
More informationCost-effectiveness ratios are commonly used to
... HEALTH ECONOMICS... Application of Cost-Effectiveness Analysis to Multiple Products: A Practical Guide Mohan V. Bala, PhD; and Gary A. Zarkin, PhD The appropriate interpretation of cost-effectiveness
More informationThe Economics of Obesity
The Economics of Obesity John Cawley Cornell University Usefulness of Economics in Studying Obesity Offers widely-accepted theoretical framework for human behavior (constrained maximization) We ask different
More informationFolland et al Chapter 4
Folland et al Chapter 4 Chris Auld Economics 317 January 11, 2011 Chapter 2. We won t discuss, but you should already know: PPF. Supply and demand. Theory of the consumer (indifference curves etc) Theory
More informationIncremental cost-effectiveness of initial cataract surgery Busbee B G, Brown M M, Brown G C, Sharma S
Incremental cost-effectiveness of initial cataract surgery Busbee B G, Brown M M, Brown G C, Sharma S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More information! Parallels with clinical studies.! Two (of a number of) concerns about data from trials.! Concluding comments
TRIAL-BASED ECONOMIC EVALUATIONS: CAN THEY STAND ALONE? Henry Glick Division of General Internal Medicine University of Pennsylvania www.uphs.upenn.edu/dgimhsr International Health Economics Association
More informationMaking Economic Evaluation Fit for Purpose to Guide Resource Allocation Decisions
Making Economic Evaluation Fit for Purpose to Guide Resource Allocation Decisions Mark Sculpher, PhD Professor of Health Economics Centre for Health Economics University of York, UK Outline Policy context
More informationPreventive Care: A National Profile on Use, Disparities, and Health Benefits
Eduardo Sanchez, MD, MPH Director, Institute for Health Policy University of Texas School of Public Health Chair, National Commission on Prevention Priorities Preventive Care: A National Profile on Use,
More informationThe long-term cost-effectiveness of bariatric surgery for the treatment of severe obesity: a cost utility analysis from a societal perspective
The long-term cost-effectiveness of bariatric surgery for the treatment of severe obesity: a cost utility analysis from a societal perspective Presented By: Erica Lester MD MSc Disclosure I have no actual
More informationFLURESP Cost-Effectiveness of Public Health Interventions against Human Influenza. Ariel Beresniak, MD, MPH, PhD Fluresp Project Leader
FLURESP Cost-Effectiveness of Public Health Interventions against Human Influenza Ariel Beresniak, MD, MPH, PhD Fluresp Project Leader FLURESP European consortium FLURESP is the first and only project
More informationBreastfeeding support, designed to encourage greater initiation and duration, can take
Modelling the Cost-effectiveness of breastfeeding support Introduction Breastfeeding support, designed to encourage greater initiation and duration, can take many forms: Peer support paid and voluntary
More informationPharmacoeconomics: from Policy to Science. Olivia Wu, PhD Health Economics and Health Technology Assessment
Pharmacoeconomics: from Policy to Science Olivia Wu, PhD Health Economics and Health Technology Assessment Potential conflicts of interest - none 2 Pharmacoeconomics: from policy to science - Why the need
More informationTIPI di ANALISI ECONOMICHE Patrizia Berto LASER Analytica - Milano
TIPI di ANALISI ECONOMICHE Patrizia Berto LASER Analytica - Milano 1 DIFFERENCE BETWEEN COST-CONTAINMENT AND COST-OPTIMIZATION Prices & volumes control Co-payments Control on prescriptions Allocation of
More informationEconomic Evaluation. Introduction to Economic Evaluation
Economic Evaluation Introduction to Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of
More informationStratified Cost-Effectiveness Analysis (with implications for sub-group analysis) (and applications to value-based pricing)
Stratified Cost-Effectiveness Analysis (with implications for sub-group analysis) (and applications to value-based pricing) Andrew H Briggs William R Lindsay Chair of Health Economics Stratified CEA: Overview
More informationCost-Effectiveness of Fractional Flow Reserve
Cost-Effectiveness of Fractional Flow Reserve William F. Fearon, MD Associate Professor of Medicine Director, Interventional Cardiology Stanford University Medical Center Cost-Effectiveness of FFR What
More informationUsing Health Economics to Inform the Development of Medical Devices. Matthew Allsop MATCH / BITECIC
Using Health Economics to Inform the Development of Medical Devices Matthew Allsop MATCH / BITECIC Overview Background to MATCH Overview of health economics in product development Concepts relating to
More informationResponse to HIV LOGISTICAL AND OTHER PERSPECTIVES
Response to HIV LOGISTICAL AND OTHER PERSPECTIVES Margaret Brandeau Department of Management Science and Engineering Department of Medicine Stanford University Topics HIV: A humanitarian crisis Planning
More informationA Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making
Presenter: Chris Cameron CANNeCTIN November 8, 2013 A Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making Acknowledgements Vanier
More informationMarc Baguelin 1,2. 1 Public Health England 2 London School of Hygiene & Tropical Medicine
The cost-effectiveness of extending the seasonal influenza immunisation programme to school-aged children: the exemplar of the decision in the United Kingdom Marc Baguelin 1,2 1 Public Health England 2
More informationCost-effectiveness of Influenza Vaccine
Cost-effectiveness of Influenza Vaccine Lisa A. Prosser, PhD, MS Associate Professor University of Michigan National Influenza Vaccine Summit May 16, 2012 Acknowledgments Funding for this research project
More informationStudy population The study population comprised type 1 and 2 diabetic patients without renal complications.
Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines van Os N, Niessen L W, Bilo H J, Casparie A F, van Hout B A Record Status This is a critical abstract
More informationUsing CEA to inform state policy 30 November 2017
E: jshoch@ucdavis.edu T: @j_hoch https://twitter.com/j_hoch USING COST- EFFECTIVENESS ANALYSIS TO INFORM STATE POLICY Health Policy and Management Jeffrey S. Hoch, PhD Associate Director, Center for Healthcare
More informationBringing Together Health Economics and Clinical Research
Bringing Together Health Economics and Clinical Research Mark Sculpher, PhD Professor of Health Economics University of York, UK Economics of Cancer Workshop, 28 th October 2011 Background Long tradition
More informationCost-Utility Analysis (CUA), part II
Cost-Utility Analysis (CUA), part II Marcelo Coca Perraillon University of Colorado Anschutz Medical Campus Cost-Effectiveness Analysis HSMP 6609 2016 1 / 38 Review Last class we saw the way health states
More informationRole of Economic Epidemiology: With Special Reference to HIV/AIDS
Role of Economic Epidemiology: With Special Reference to HIV/AIDS Senelani Dorothy Hove-Musekwa NUST AIMS Bulawayo Cape Town Zimbabwe South Africa Economic Epidemiology Workshop - Uganda: 3 August 2009
More informationHealth Economics 101: PPI prescriptions in the Emergency Room
: PPI prescriptions in the Emergency Room Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) Presented by: Chris Cameron October 26, 2007 What is Health Economics? Health economics
More informationTitle of the presentation
. Title of the presentation Economic analyses for hepatitis elimination Subtitle of the presentation, lorem ipsum dolor sit amet. Yvan Hutin, Global Hepatitis Programme, World Health Organization November
More informationDAY 2 RESULTS WORKSHOP 7 KEYS TO C HANGING A NYTHING IN Y OUR LIFE TODAY!
H DAY 2 RESULTS WORKSHOP 7 KEYS TO C HANGING A NYTHING IN Y OUR LIFE TODAY! appy, vibrant, successful people think and behave in certain ways, as do miserable and unfulfilled people. In other words, there
More informationHealth Economics Research Centre. The cost-effectiveness of policies to reduce radon-induced lung cancer
H E R C Health Economics Research Centre The cost-effectiveness of policies to reduce radon-induced lung cancer Alastair Gray Health Economics Research Centre Department of Public Health University of
More information5 $3 billion per disease
$3 billion per disease Chapter at a glance Our aim is to set a market size large enough to attract serious commercial investment from several pharmaceutical companies that see technological opportunites,
More informationMethods of eliciting time preferences for health A pilot study
Methods of eliciting time preferences for health A pilot study Dorte Gyrd-Hansen Health Economics Papers 2000:1 Methods of eliciting time preferences for health A pilot study Dorte Gyrd-Hansen Contents
More informationCost-effectiveness Analysis for HHS
Cost-effectiveness Analysis for HHS Edward Broughton, PhD., MPH Director of Research and Evaluation, USAID ASSIST Project, University Research Co., LLC Ukraine: 1 Mali: 1 Nigeria: 1 2 Uganda: 6 Burundi:
More informationCost-Utility Analysis (CUA) Explained
Pharmaceutical Management Agency Cost-Utility Analysis (CUA) Explained Cost-Utility Analysis (CUA) at PHARMAC Questions and Answers go to page 9 >> This document explains the process that PHARMAC generally
More informationUTAH VOTERS FAVOR RAISING THE LEGAL AGE FOR THE SALE OF TOBACCO TO AGE 21.
UTAH VOTERS FAVOR RAISING THE LEGAL AGE FOR THE SALE OF TOBACCO TO AGE 21. The Salt Lake City-based public opinion and market research firm Dan Jones & Associates recently completed a survey of 515 voters
More informationShining Steel or Illegitimate Science?
Shining Steel or Illegitimate Science? Economics and Health Care Decisions Karl Claxton Department of Economics and Related Studies, Centre for Health Economics, University of York. www.york.ac.uk/inst/che
More informationEconomic Analysis of Interventions for Smoking Cessation Aimed at Pregnant Women
Y O R K Health Economics C O N S O R T I U M NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Economic Analysis of Interventions for Smoking Cessation Aimed at Pregnant Women Supplementary Report
More informationEconomic Analyses in Clinical Trials
Economic Analyses in Clinical Trials Natasha Leighl (and Nicole Mittmann) Committee on Economic Analysis, NCIC CTG Natasha.Leighl@uhn.on.ca; Nicole.Mittmann@sunnybrook.ca Financial Disclosures Research
More informationPharmacoeconomics of Trastuzumab (Herceptin )
Pharmacoeconomics of Trastuzumab (Herceptin ) Breast Cancer Press Seminar (2008.3.3) Department of Health Economics and Epidemiology Research Graduate School of Medicine, The University of Tokyo Takashi
More informationSaving Lives, Saving Families: The health, social and economic advantages of detecting and treating familial hypercholesterolaemia (FH)
1 Saving Lives, Saving Families: The health, social and economic advantages of detecting and treating familial hypercholesterolaemia (FH) Economics Chapter: Estimating the benefits from treatment and increasing
More informationThe cost-effectiveness of polypharmacy
The cost-effectiveness of polypharmacy 25 September 2012 Thomas A. Gaziano MD MSc Division of Cardiovascular Medicine Harvard Medical School Program for Health Decision Science Harvard School of Public
More informationPertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A
Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationb de HPV Vaccination of School-Age Girls comparing the cost-effectiveness of 3 delivery programmes SUMMARY
b de HPV Vaccination of School-Age Girls comparing the cost-effectiveness of 3 delivery programmes SUMMARY Human papillomaviruses (HPV) are common sexually transmitted viruses. They can cause several types
More informationHow to evaluate the economic impact of interventions I: introduction and costing analyses
How to evaluate the economic impact of interventions I: introduction and costing analyses Raymond Hutubessy Initiative for Vaccine Research (IVR), Geneva, Switzerland Mark Jit WHO consultant, Health Protection
More informationSaving lives and resources by preventing osteoporotic fractures with dairy products
Saving lives and resources by preventing osteoporotic fractures with dairy products CERIN-EMF-GDP LUNCH SYMPOSIUM Dr Mickael Hiligsmann, PhD Assistant Professor in Health Economics and Health Technology
More informationBack to the future: should we live in a post-qaly world?
Back to the future: should we live in a post-qaly world? Moderator: John Spoors, Senior Analytical Lead, NHS By Ad England Rietveld john.spoors@nhs.net RJW&partners Presenters: Andrew Walker Ad Rietveld
More informationA. Introduction to Health Economics. Dr Alan Haycox Reader in Health Economics Health Economics Unit University of Liverpool Management School
A. Introduction to Health Economics Dr Alan Haycox Reader in Health Economics Health Economics Unit University of Liverpool Management School Introduction to Health Economics Programme The programme will
More informationULTIMATUM GAME. An Empirical Evidence. Presented By: SHAHID RAZZAQUE
1 ULTIMATUM GAME An Empirical Evidence Presented By: SHAHID RAZZAQUE 2 Difference Between Self-Interest, Preference & Social Preference Preference refers to the choices people make & particularly to tradeoffs
More informationPrinciples of decisions making at NICE
Principles of decisions making at NICE Karl Claxton Simon Walker Stephen Palmer Mark Sculpher Centre for Health Economics University of York, UK CHE/OHE Workshop, What perspective should be used in health
More informationAn exploration of the cost-effectiveness of interventions to reduce. differences in the uptake of childhood immunisations in the UK using
An exploration of the cost-effectiveness of interventions to reduce differences in the uptake of childhood immunisations in the UK using threshold analysis National Collaborating Centre for Women s and
More informationSCREENING FOR ATRIAL FIBRILLATION IN CANADIAN PHARMACIES IS COST-EFFECTIVE
SCREENING FOR ATRIAL FIBRILLATION IN CANADIAN PHARMACIES IS COST-EFFECTIVE Jean-Eric Tarride PhD, Lisa Dolovich PharmD MSc, Gordon Blackhouse MSc, MBA, Jason Guertin PhD, Natasha Burke MSc, Veena Manja
More informationDecision-Analytic Modeling of PSA Screening an ONCOTYROL Project
Decision-Analytic Modeling of PSA Screening an ONCOTYROL Project EUFEP, Baden, June 24-26, 2009 Uwe Siebert, MD, MPH, MSc, ScD Professor of Public Health (UMIT) Adjunct Professor of Health Policy and Management
More informationTell a Friend About Burn The Fat Blog
burnthefatblog.com Tell a Friend About Burn The Fat Blog A recent study from Duke University comparing aerobic versus weight training to see which is better for fat loss was one of the most publicized
More informationAn Introduction to Costeffectiveness
Health Economics: An Introduction to Costeffectiveness Analysis Subhash Pokhrel, PhD Reader in Health Economics Director, Division of Health Sciences Why do we need economic evaluation? 2017 2 Patient
More informationCost-effectiveness analysis of a screening programme. Iris Lansdorp-Vogelaar, PhD Department of Public Health Erasmus MC, Rotterdam
Cost-effectiveness analysis of a screening programme Iris Lansdorp-Vogelaar, PhD Department of Public Health Erasmus MC, Rotterdam Criteria of Wilson and Jungner (Bull World Health Organ. 1968) Why cost-effectiveness
More informationSTUDY. Cost-effectiveness and Cost-Benefit Analysis of Using Methotrexate vs Goeckerman Therapy for Psoriasis
STUDY Cost-effectiveness and Cost-Benefit Analysis of Using vs Goeckerman Therapy for A Pilot Study Suephy Chen, MD; Allison Shaheen, SB; Alan Garber, MD, PhD Objective: To analyze the net benefit and
More informationThe Economic Consequences of Diabetes: More than just a health issue
The Economic Consequences of Diabetes: More than just a health issue Dr Hannah Carter ADEA-QLD Conference 21 April 2018 Overview The Cost of Illness (COI) framework Direct costs of diabetes Indirect costs
More informationThe New Drugs: Are They Worth It? A PHARMACOECONOMIC PERSPECTIVE
The New Drugs: Are They Worth It? A PHARMACOECONOMIC PERSPECTIVE Niteesh K. Choudhry, MD, PhD Associate Professor, Harvard Medical School Associate Physician, Division of Pharmacoepidemiology and Pharmacoeconomics,
More informationReporting and Interpreting Results of Economic Evaluation
Reporting and Interpreting Results of Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of
More informationHealth technology Prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients Grann V R, Panageas K S, Whang W, Antman K H, Neugut A I Record Status This is a critical abstract
More informationCost-effectiveness of measuring fractional flow reserve to guide coronary interventions Fearon W F, Yeung A C, Lee D P, Yock P G, Heidenreich P A
Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions Fearon W F, Yeung A C, Lee D P, Yock P G, Heidenreich P A Record Status This is a critical abstract of an economic
More informationNICE AAA Guidelines. Professor Andrew W. Bradbury
NICE AAA Guidelines Professor Andrew W. Bradbury Sampson Gamgee Professor of Vascular Surgery University of Birmingham, UK Thursday 29 November 2018 14.00-14.15 Alsh NICE Guidelines: international reputation
More informationSetting up the game. How to play. Keeping Score
Setting up the game Two players or more per team Teams don t have to be even or equal size Each team needs to designate a score keeper How to play The game will be played for 5 consecutive weeks Each player
More informationModule 1 What is economics and economic evaluation?
Designing Economic Evaluation Alongside Clinical Studies Health Economics Short Course For more information and course dates, please visit our website http://mdhs-study.unimelb.edu.au/short-courses/mspghshort-courses/designing-economic-evaluation-alongsideclinical-studies/overview
More informationHelicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment Pohl H, Finlayson S R, Sonnenberg A, Robertson D J
Helicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment Pohl H, Finlayson S R, Sonnenberg A, Robertson D J Record Status This is a critical abstract of an economic
More informationinitial DUS imaging followed by contrast-enhanced magnetic resonance angiography (CEMRA) when DUS demonstrates 50% or higher stenosis;
Cost-effectiveness of diagnostic strategies prior to carotid endarterectomy U-King-Im J M, Hollingworth W, Trivedi R A, Cross J J, Higgins N J, Graves M J, Gutnikov S, Kirkpatrick P J, Warburton E A, Antoun
More informationClicker quiz: Should the cocaine trade be legalized? (either answer will tell us if you are here or not) 1. yes 2. no
Clicker quiz: Should the cocaine trade be legalized? (either answer will tell us if you are here or not) 1. yes 2. no Economic Liberalism Summary: Assumptions: self-interest, rationality, individual freedom
More informationDeveloping an ethical framework for One Health policy analysis: suggested first steps
Developing an ethical framework for One Health policy analysis: suggested first steps Joshua Freeman, Clinical Microbiologist, Canterbury DHB Professor John McMillan Bioethics Centre, University of Otago
More informationThe cost of cancer treatment
The cost of cancer treatment Lieven Annemans Ghent University Lieven.annemans@ugent.be January 2016 What s the problem? those prices are too high the budgets will explode these drugs offer survival benefit
More informationSource of effectiveness data The effectiveness evidence came from a review of published studies and the authors' assumptions.
Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond Tice J A, Ross E, Coxson P G, Rosenberg
More informationDoing Double Duty Collecting Data for FDA and CMS in the Same Study
Doing Double Duty Collecting Data for FDA and CMS in the Same Study Gregory de Lissovoy, PhD MEDICAL DEVICE REGULATORY AND COMPLIANCE CONGRESS March 30, 2006 Overview How FDA and CMS view evidence from
More informationCONDUCTING TRAINING SESSIONS HAPTER
7 CONDUCTING TRAINING SESSIONS HAPTER Chapter 7 Conducting Training Sessions Planning and conducting practice sessions. It is important to continually stress to players that through practice sessions
More information(a) Perform a cost-benefit analysis of diabetes screening for this group. Does it favor screening?
Cameron ECON 132 (Health Economics): SECOND MIDTERM EXAM (A) Winter 18 Answer all questions in the space provided on the exam. Total of 36 points (and worth 22.5% of final grade). Read each question carefully,
More informationIntroduction to Cost- Effectiveness Analysis. Brennan Spiegel, MD, MSHS
Introduction to Cost- Effectiveness Analysis Brennan Spiegel, MD, MSHS VA Greater Los Angeles Healthcare System David Geffen School of Medicine at UCLA CURE Digestive Diseases Research Center UCLA/VA Center
More informationUNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator
UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator QOF indicator area: Hypertension Under 80 Potential output:
More informationOne goal of health policy should be to develop
The Role of Resource Allocation Models in Selecting Clinical Preventive Services Li Yan Wang, MBA, MA; Anne C. Haddix, PhD; Steven M. Teutsch, MD, MPH; and Blake Caldwell, MD, MPH Abstract Objective: To
More informationEconomic evaluation of tandem mass spectrometry screening in California Feuchtbaum L, Cunningham G
Economic evaluation of tandem mass spectrometry screening in California Feuchtbaum L, Cunningham G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationWhen does quality-adjusting life-years matter in cost-e ectiveness analysis? y
HEALTH ECONOMICS ECONOMIC EVALUATION Health Econ. 13: 429 436 (2004) Published online 4 March 2004 in Wiley InterScience (www.interscience.wiley.com). DOI:10.1002/hec.853 When does quality-adjusting life-years
More informationCost-effectiveness of a pediatric dengue vaccine Shepard D S, Suaya J A, Halstead S B, Nathan M B, Gubler D J, Mahoney R T, Wang D N, Meltzer M I
Cost-effectiveness of a pediatric dengue vaccine Shepard D S, Suaya J A, Halstead S B, Nathan M B, Gubler D J, Mahoney R T, Wang D N, Meltzer M I Record Status This is a critical abstract of an economic
More informationStudy Designs. Lecture 3. Kevin Frick
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationWHAT TO DO IN ABSENCE OF HEAD TO HEAD CLINICAL TRIAL DATA. Lead the economic evaluation group at CHERE, University of Technology, Sydney
WHAT TO DO IN ABSENCE OF HEAD TO HEAD CLINICAL TRIAL DATA MIXED TREATMENT COMPARISON (MTC) Stephen Goodall, Associate Professor of Health Economics Centre for Health Economics Research and Evaluation,
More informationThe cost-effectiveness of screening for latent tuberculosis infection
INT J TUBERC LUNG DIS 4(12):S127 S133 2000 IUATLD The cost-effectiveness of screening for latent tuberculosis infection Z. Taylor Division of Tuberculosis Elimination, Centers for Disease Control and Prevention,
More informationType of intervention Secondary prevention and treatment; Other (medication coverage policy design).
Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes Rosen A B, Hamel M B, Weinstein M C, Cutler D M, Fendrick A, Vijan S Record Status
More informationEconomic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean?
CA Cancer J Clin 2008;58:231 244 Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean? Ya-Chen Tina Shih, PhD; Michael T. Halpern, MD, PhD ABSTRACT While
More information2017 학년도수능연계수능특강 영어영역영어. Lecture 03. 요지추론 - 본문. The negative effects of extrinsic motivators such as grades
다음글의요지로가장적절한것은? The negative effects of extrinsic motivators such as grades have been documented with students from different cultures. Although this matter is more complex than simply regarding all extrinsic
More informationValue Based Health Care in the UK: NICE, VBP and the Cost-effectiveness Threshold. Eldon Spackman, MA, PhD
Value Based Health Care in the UK: NICE, VBP and the Cost-effectiveness Threshold Eldon Spackman, MA, PhD Background to NICE NICE s current position on the threshold Two concepts of the threshold Why the
More informationBasic Economic Analysis. David Epstein, Centre for Health Economics, York
Basic Economic Analysis David Epstein, Centre for Health Economics, York Contents Introduction Resource use and costs Health Benefits Economic analysis Conclusions Introduction What is economics? Choices
More informationCost-Effectiveness Analysis of TB Diagnostics David Dowdy Challenges and Future Directions
Cost-Effectiveness Analysis of TB Diagnostics David Dowdy ddowdy@jhsph.edu Challenges and Future Directions Objectives Provide an overview of cost-effectiveness analysis (CEA) as applied to TB diagnostics
More informationNational Primary Care Research and Development Centre and University of York Health Economics Consortium (NICE External Contractor)
National Primary Care Research and Development Centre and University of York Health Economics Consortium (NICE External Contractor) July 2010 Health economic report: threshold analysis This paper was prepared
More information+ Economic Analyses in Clinical
+ Economic Analyses in Clinical Trials Nicole Mittmann (and Natasha Leighl) Committee on Economic Analysis (formerly, Working Group on Economic Analysis, NCIC CTG) Natasha.Leighl@uhn.on.ca; Nicole.Mittmann@sunnybrook.ca
More informationStudy population The study population comprised patients with nephropathy from Type II diabetes.
Losartan reduces the costs associated with nephropathy and end-stage renal disease from Type 2 diabetes: economic evaluation of the RENAAL study from a Canadian perspective Burgess E D, Carides G W, Gerth
More informationCost-effectiveness of influenza immunisation programmes
High-level hearing on the implementation of the Council Recommendation on seasonal influenza vaccination, Luxembourg, 29-30 April 2015 Cost-effectiveness of influenza immunisation programmes Mark Jit Modelling
More informationAddressing health equity concerns in costeffectiveness
Addressing health equity concerns in costeffectiveness analysis? Distributional Cost-Effectiveness Analysis Miqdad Asaria m.asaria@lse.ac.uk @miqedup Overview 1) Introduction 2) Distributional CEA 3) Case
More informationTownsville Broadband Diabetes Telehealth Trial EVALUATION REPORT. May 2015
Townsville Broadband Diabetes Telehealth Trial EVALUATION REPORT May 2015 A report by the Centre for Applied Health Economics (CAHE), Griffith University www.healtheconomics.com.au EXECUTIVE SUMMARY BACKGROUND
More informationUNIVERSITY OF CALGARY. Cost-effectiveness of chest x-ray screening for diagnosis and treatment of inactive. Dina Avalee Fisher A THESIS
UNIVERSITY OF CALGARY Cost-effectiveness of chest x-ray screening for diagnosis and treatment of inactive pulmonary tuberculosis in a high-incidence country by Dina Avalee Fisher A THESIS SUBMITTED TO
More informationThe cost-effectiveness of interventions in primary care a health economic perspective for decision-making. Miika Linna, Aalto University/HEMA
The cost-effectiveness of interventions in primary care a health economic perspective for decision-making Miika Linna, Aalto University/HEMA Introduction 1) Cost-effectiveness and quality improvement differences
More informationNICE Guidelines for HTA Issues of Controversy
NICE Guidelines for HTA Issues of Controversy Mark Sculpher, PhD Professor of Health Economics University of York, UK LMI, Medicines Agency in Norway and the Norwegian Knowledge Centre for the Health Services:
More informationChoice of EQ 5D 3L for Economic Evaluation of Community Paramedicine Programs Project
As articulated in the project Charter and PICOT Statement, the Economic Value of Community Paramedicine Programs Study (EV-CP) will seek to determine: The economic value of community paramedicine programs
More informationThose who think they have not time for bodily exercise will sooner or later have to find time for illness.
MAY 2016 POWERED BY QUOTE OF THE MONTH Those who think they have not time for bodily exercise will sooner or later have to find time for illness. - EDWARD STANLEY Physical Fitness & Sports Month Spring
More information